Abstract
Targeted radionuclide/radiopeptide therapies (TRT) provide chemotherapy-free cancer treatment. However, TRT carries a risk of secondary myelodysplasia/acute leukaemia (MDS/AL). This research analyses the long-term safety and efficacy of TRT delivered to Western Australian cancer patients. The incidence of MDS/AL was low (1-3%) in patients treated withlutetium-177-octreotate for neuroendocrine tumours, iodine-131-rituximab for follicular lymphoma and lutetium-177 prostate specific membrane antigen for advanced prostate cancer. An increased incidence is apparent in patients with prior/concurrent alkylator exposure and depleted marrow reserve, there is an unmet need to improve patient selection and monitoring based upon inherent genetic risk.
| Original language | English |
|---|---|
| Qualification | Doctor of Philosophy |
| Awarding Institution |
|
| Supervisors/Advisors |
|
| Thesis sponsors | |
| Award date | 6 Mar 2022 |
| DOIs | |
| Publication status | Unpublished - 2021 |
Access to Document
- THESIS - DOCTOR OF PHILOSOPHY - KESAVAN, Murali - 2021 - Part 3
This work is protected by Copyright. You may print or download ONE copy of this document for the purpose of your own non-commercial research or study. Any other use requires permission from the copyright owner. The Copyright Act requires you to attribute any copyright works you quote or paraphrase.